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Insomnia: Its Causes, Its Consequences, and Its Cures
Shoshana Fried

ABSTRACT
Insomnia is a complaint that affects almost all Americans at some point throughout their
lives. However, only chronic insomnia is truly a disorder. This type of insomnia can be caused
by various reasons, whether physiological, molecular, or psychological. This paper will elaborate
on a number of possible causes for insomnia. Furthermore, this paper will present some of the
many adverse effects that are caused by the sleep deprivation resulting from chronic insomnia.
There are many possible treatments available to help against insomnia. This paper will explain
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some of the behavioral methods. In addition, it will discuss the many different medications that
have been used or are still used to treat insomnia, including chloral hydrate, barbiturates,
antihistamines, and antidepressants. This paper will show the benefits and risks of
benzodiazepines, a class of drugs used to treat insomnia, as well as the benefits and risks or the
benzodiazepine-like agents BZRAs. This paper will also mention the new EVT 201drug for
insomnia that is currently undergoing testing for its efficacy and safety. In conclusion, this paper
will show that each case of insomnia is unique and different, from its cause to its ramifications.
Each case must be dealt with and treated individually.
Most people spend about a quarter of their lives sleeping. That’s about forty-two hours a
week, ninety-one days per year, and, in a lifetime of ninety years, over twenty of them will be
spent asleep. Many think of this as wasted time; we cannot accomplish many things on out “To
Do” lists while snoozing. However, sleep is an important and essential need of the body, and in
fact one could not live long without it. Many restorative and healthy benefits take place during
those hours of sleep, making sleep quite necessary for life.
Various parts of the brain are responsible for or involved in sleep, and a few theories
exist as to how we fall asleep. The generally accepted view today is that several parts of the brain
are involved in sleep regulation. In some areas of the brain, neurotransmitters such as serotonin
and norepinephrine are produced by neurons in the brainstem and act on different groups of
neurons. Whether we are asleep or awake depends on which neurons receive the signals. In other
cases, neurons begin to signal only once we fall asleep. These activated neurons are believed to
switch off the signals and keep us awake (NINDS ’04). One area of the brain involved in sleep
regulation is the raphe’ nuclei which are located in a thin strip down the midline of the caudal
reticular formation. It is believed that these nuclei promote sleep (Pinel ’03). The basal forebrain
region and the nearby anterior hypothalamus are also thought to be instrumental in promoting
sleep (Pinel ’03). Sites throughout the caudal reticular formation are thought to be responsible
for controlling the major indices of REM sleep, the stage of sleep most physiologically similar to
wakefulness. Different sites control different features of REM sleep, such as core muscle
relaxation, cardiorespiratory changes, and rapid eye movements.
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These sites communicate through cholinergic and monoaminergic neurons located in the caudal
reticular formation. If all these areas work together, REM sleep is induced (Pinel ’03).
Why do we sleep? What do we gain? According to many studies done on both animals
and humans, much. Sleep is necessary for survival. According to the recuperation theories of
sleep, the body’s homeostasis is disrupted while one is awake. Sleep restores the body to
homeostasis, for example restoring the body’s energy levels. These theories imply that when a
great deviation from homeostasis results after a period of wakefulness, sleepiness is triggered
and the person will go to sleep. Once homeostasis is reestablished, the person wakes up (Pinel
’03).
Another theory proposed is that sleep is necessary for our nervous system to properly
function. Sleep gives regularly active neurons a chance to rest and repair themselves while using
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other groups of neurons during sleep. Without sleep, daytime neurons would become energy
depleted or so clogged up with metabolic byproducts that they would malfunction (NINDS ’04).
Sleep also allows for certain neuronal connections that do not regularly occur during
wakefulness, which otherwise might degenerate from misuse (NINDS ’04).
Additionally, many cells in the body show higher rates of protein production during
sleep. These proteins are necessary for cell growth and repair. In children and young adults,
release of growth hormone occurs during deep sleep (NINDS ’04). When a person’s body has an
infection, he or she sleeps more due to the increased levels of cytokines, which are powerful
sleep-inducing chemicals. This indicates that sleep may help conserve energy and other
resources that the immune system can now use to attack the source of infection (Dunn ’04).
The benefits of sleep are many, indicating that sleep is extremely significant. Not only is
sleep relaxing and restorative, it is also actively beneficial. Sleep helps the body maintain its
normal metabolism and activity, and that is why a deficit of sleep is so detrimental.
Insomnia is defined as “the sensation of daytime fatigue and impaired performance
caused by insufficient sleep” (A.D.A.M. ’03). Insomnia is divided into three categories, based on
its duration. Transient insomnia, which is experienced by 35% of Americans (Caldwell ’03), is
the inability to fall asleep for a few nights. Short-term insomnia lasts for up to three weeks.
Chronic insomnia, which is the truly problematic type, is defined when a person finds it difficult
to fall asleep or maintain sleep or he feels his sleep is nonrestorative for at least three nights a
week for a month or more (A.D.A.M. ’03). The patient also must be in distress and believe that
his or her normal daily functioning is suffering from the sleep loss (A.D.A.M. ’03).
Transient and short-term insomnia can have many causes. These types of insomnia can
often be a response to a change or a stress, such as travel, an acute illness, a job change, or even
an exam. These symptoms are minor and only last for a short while; when the stress is removed
or the person adjusts to the change, the insomnia stops and normal sleep returns. Transient or
short-term insomnia can often occur in females due to fluctuations in hormones, such as during
menstruation or pregnancy. Changes in the amount of light to which a person is exposed can
influence his or her ability to fall asleep, along with noise, uncomfortable temperatures, or other
environmental disruptions (A.D.AM. ’03). Increases muscle tension, caused by daily stress, will
not allow a person to fall asleep easily (Caldwell ’03). Ingesting certain substances, such as
caffeine or nicotine, can disrupt sleep and generate insomnia. Many medications include
insomnia as a side effect, especially those containing caffeine (A.D.A.M. ’03). However, in all
these cases, unless the insomnia persists for more than a few weeks, no treatment is necessary.
Chronic insomnia, however, is more significant. Chronic insomnia is usually caused by a
collaboration of different psychological and physical conditions. One important kind of insomnia
is psychophysiologic insomnia which is caused by initial transient insomnia. After experiencing
difficulty falling asleep for a few nights, the patient begins to associate the bed with a struggle to
sleep. This causes even more difficulty in falling asleep. Eventually the patient begins to worry
excessively about sleep loss and continually experiences anxiety at bedtime. This cycle continues
over a log period and the insomnia becomes chronic (A.D.A.M. ’03).
Chronic insomnia can also be caused by pain or discomfort. Leg disorders especially,
such as restless leg syndrome or leg cramps, are often a cause of insomnia. Other medical
problems that can cause insomnia include arthritis, heart disease, asthma, Attention Deficit
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Hyperactivity Disorder (ADHD), and cancer. Many medications as well induce insomnia. These
medications include beta-blockers, certain antidepressants, beta-agonists, and many more. When
taken over a long period of time, they can produce chronic insomnia. Substance abuse, especially
overuse of alcohol or cocaine, can also play a major role in causing insomnia (A.D.A.M. ’03).
Very often insomnia has an underlying psychological cause. Certain emotional disorders
often cause insomnia, especially anxiety, bipolar disorder, and depression. These emotional
disorders prevent the relaxation necessary for sleep onset (Caldwell ’03). They also often cause
repeated awakenings during the night and the inability to return to sleep after awakening
(A.D.A.M. ’03).
Insomnia can be annoying. Lying in bed for hours waiting to fall asleep can be
frustrating, and waking up repeatedly throughout the night can be exasperating. However, the
effects of sleep deprivation are much more significant and detrimental than that.
Sleep deprivation can cause a decline in certain cognitive abilities. The National Sleep
Foundation (NSF) lists a number of consequences of inadequate sleep, including slow thinking
or reacting and frequent mistakes. They also include difficulty focusing, a narrowing of attention,
difficulty following directions, difficulty remembering information, and poor judgment regarding
complex situations (A.D.A.M. ’03). Sleep deprivation can also cause impairment of higher
neurological functions. Awareness and perception decline, and vision difficulties often occur.
Difficulty with coordination and fine motor skills is also quite common (Caldwell ’03). General
performance declines and simple tasks become more difficult or even impossible.
Even more unsettling are the emotional problems caused by inadequate sleep. Sleep
deprivation often has an adverse effect on mood or temperament. The NSF includes in its list
impatience and quick anger, as well as depression or negative mood. [j] Insomnia can interfere
with the activity of hormones and pathways that deal with emotion, so that even minimal sleep
deprivation can greatly effect one’s mood (A.D.A.M. ’03).
When one has had inadequate sleep, one is more likely to feel forlorn, depressed, or
hopeless. Lack of sleep also causes motivation to diminish. In addition to the actual decline in
cognitive abilities due to his sleep deprivation, insomnia also causes a person’s desire and
interests to lessen. He would much rather rest than do a math problem or solve a puzzle. Perhaps
this is what account for the great disparity in performance when one is sleep deprived (Caldwell
’03). The negative repercussions that result from sleep deprivation can decrease the quality of
life as much as living with a chronic condition like heart failure (A.D.A.M. ’03).
During periods of inadequate sleep, many abnormal physiological conditions are
observed. A study done in 1991 found that after a single night of three hours of sleep, during
submaximal exercise maximum oxygen consumption significantly decreased while heart rate and
ventilation significantly increased. A 1993 study investigating the endocrinological effects of
sleep deprivation found that TSH, thyroid hormones, estradiol, and LH levels went up, while
prolactin levels decreased (Walsh and Lindbolm ’97). Although the reasons for these changes are
unclear, their message is not: Sleep deprivation causes many changes in the body’s metabolism,
and most of them are evidently not very beneficial.
Chronic sleep loss adversely affects metabolic functions, in particular carbohydrate
metabolism. A study done at the University of Chicago in 1999 found that after a period of sleep
deprivation, glucose conditions were higher than they were after a period of adequate rest (Van
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Cauter ’99). These variations in glucose metabolism resembled those in patients with type-2
diabetes (The University of Chicago Medical Center ’99). A subsequent study was conducted in
2006 by the same author. The HbA1c, glycosylated hemoglobin which reflects the average blood
glucose blood level over the previous three months, was measured in various patients already
diagnosed with diabetes. They found that higher HbA1c results were closely associated with
inadequate or poor quality sleep. This study showed that insufficient proper sleep is related to
increased blood glucose levels in patients with diabetes (The University of Chicago Medical
Center ’06).
The 1999 study concluded that the reduction of metabolic function capacity due to
chronic sleep loss is devastating. The metabolic and endocrine changes that result “mimic many
of the hallmarks of aging”. Cutting back on sleep “produced striking changes in glucose
tolerance and endocrine function-changes that resembled the effects of advanced age or the early
stages of diabetes.” These results occurred after less than a week of sleep deficiency! This study
showed that chronic sleep loss can “hasten the onset but could also increase the severity of agerelated ailments such as diabetes, hypertension, obesity and memory loss” (The University of
Chicago Medical Center ’06).
Besides altering endocrine and metabolic functions, sleep deprivation can also have an
adverse effect on the immune system. In a study done in 2002, influenza vaccinations were given
to two groups of people. One group had been restricted to four hours of sleep for the previous
four nights, while the other group had maintained their usual bedtimes before receiving the
vaccination. It was found that those in the group of decreased sleep had mean antibody titers less
than half of those in the group with normal sleep times. The authors concluded that “the response
to influenza vaccination may be impaired in individuals with chronic partial sleep restriction”
Titers at Baseline and 1 O Days Following Influenza Vaccination
(Lurie Antibody
’02).
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weakened immune system makes people deprived of sleep more vulnerable to diseases and
infections (Dunn ’04). In a study done by the American Cancer Society, they found that men
who slept for less than four hours a night had mortality rates ten times greater than those who
slept seven to eight hours a night. Perhaps that is why the National Center for Health Service
Research in the United States considers proper amount of sleep one of the six most important
factors affecting illness and death rates (Caldwell ’03).
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Insomnia is not a disease but a symptom (Caldwell ’03). However, insomnia can
be cured- not only by taking care of the underlying cause but also by treating the insomnia itself.
There are many behavioral therapies and other treatments to stop insomnia that do not involve
medications. In addition, hypnotic drugs, which are the class of drugs that can bring on sleep,
lengthen sleep time, or improve it in any way (Caldwell ’03).
Behavioral techniques are often favored over medications for many reasons. Using
drugs always introduces side effects, interactions, and other restrictions, while making
adjustments in behavioral often does not. Behavioral methods can be used by all insomniacs,
including those already taking an incompatible medication or elderly patients. Additionally,
although medications are equally or even more effective, behavioral techniques often work faster
(A.D.A.M. ’03).
There are a number of behavioral approaches for treating insomnia. The first step
usually recommended is to check for proper sleep hygiene. This term is used “to describe simple
behaviors that may help improve sleep” (Bootzin and Rider ’97). Behaviors that constitute
improper sleep hygiene are identified and stopped. These include spending too much time in bed,
using substances like caffeine or nicotine that interfere with sleep, attempting to sleep in a poor
sleep environment, napping in the late afternoon or evening, and engaging in extremely stressful
or exciting activities close to bedtime (Bootzin and Rider ’97). Instead, proper sleep behaviors
are set. These behaviors may include establishing a fixed time for going to bed and getting up,
taking a hot bath about one and a half to two hours before bedtime, or doing something relaxing
such as reading or meditating half an hour before bedtime (A.D.A.M. ’03). Proper sleep hygiene
education has proven quite effective, often even after only one or two sessions of evaluation and
recommendations (Bootzin and Rider ’97).
One suggestion made to improve sleep hygiene is to exercise in the early evening. A few
hours after exercise, a low point in energy is experienced, and this can help the person to fall
asleep more easily (A.D.A.M. ’03). Engaging in moderate to heavy exercise causes one to fall
asleep more quickly, wake up less often throughout the night, and experience increased amounts
of deep sleep (Caldwell ’03).
Another behavioral treatment used for insomnia is stimulus control instructions. These
are a set of instructions that focus primarily on helping the patient associate the bed with falling
asleep quickly. Some of the instructions include going to bed only when ready for sleep, as well
as getting out of bed and leaving the bedroom if unable to fall asleep within ten minutes. Studies
have found stimulus control to be one of the most effective therapies for treating insomnia
(Bootzin and Rider ’97).
There are other behavioral techniques that can be used in the treatment of insomnia.
Some of these techniques are light therapy, progressive muscle relaxation, and cognitive
behavior therapy (A.D.A.M. ’03). However, the value of these methods is not so certain and
many do not provide conclusive evidence as to their effectiveness. Experts are still studying the
benefits and helpfulness of each, and studies are still being conducted to find more ways to help
in the treatment of insomnia.
Sometimes, however, behavioral methods are not enough. Each individual’s patient’s
case of insomnia is unique, and the treatment provided must match in each case. Sometimes the
behavioral techniques do not work well enough, and other proven methods must be used.
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Medications can also be helpful in the treatment of insomnia. Some over-the-counter drugs and
even drugs regularly given to treat a different symptoms- can be helpful, and sometimes doctors
might prescribe a specific medication to treat insomnia.
One drug that was formerly very common as a remedy for insomnia is chloral hydrate. It
has been in use for more than one hundred fifty years (A.D.A.M. ’03). Chloral hydrate works
quickly, reaching peak blood levels within an hour (Caldwell ’03). It has a fairly short half-life
so does not usually produce a hangover after awakening. However, its popularity as a treatment
for insomnia has gone down, due to the many adverse side effects and risks it involves. As a
direct brain-cell depressant, chloral hydrate can interfere with brain functions and cause
confusion and drowsiness (Caldwell ’03). It can also cause inflammation of the skin or irritation
of the stomach (A.D.A.M. ’03). Because it is metabolized in the liver and excreted in urine,
patients with liver or kidney disorders should not use it (Caldwell ’03). Chloral hydrate also has
carcinogenic properties and may damage genetic material. Additionally, the lethal dose of chloral
hydrate is very close to the therapeutic dose, and even a slight overdose can be fatal (Pagel and
Parnes ’01). Because of all the risks it incurs, chloral hydrate is no longer regularly used in the
treatment of insomnia.
Barbiturates is another class of drugs that can be used to treat insomnia. Barbiturates
were used as the standard sleeping medication in the years before the 1060’s (Pagel and Parnes
’01). However, addiction and abuse of barbiturates were quite common (A.D.A.M. ’03). They
also have a high danger of overdose and have caused the deaths of many, including some famous
celebrities like Elvis Presley and Marilyn Monroe (Pagel and Parnes ’01). Presently, due to their
potential for abuse and overdoes, these drugs are rarely or never prescribed to treat insomnia
(A.D.A.M. ’03).
Antihistamines are another type of drug used in the treatment of insomnia.
Antihistamines are regularly prescribed to unclog congestion from a common cold or to stop
allergic reaction that might become dangerous. A very prominent side effect of antihistamines is
sedation. Everyone knows that taking Sudafed or Benadryl will cause one to fall asleep. For
certain antihistamines, this side effect is so pronounces that it was decided to market the drugs
for insomnia. These antihistamines include diphenhydramine, the one ingredient in the most
over-the-counter “sleeping pills,” diphenhydramine, promethazine, and meclizine. However, in
most antihistamines leave patients feeling drowsy the next day (A.D.A.M. ’03). They also cause
some other adverse side effects, such as dizziness, blurred vision, increased heart rate, and
weight gain (Caldwell ’03).
Over-the-counter sleeping pills are used by 3/1% of adults in the United States (Pagel and
Parnes ’01). These antihistamines are quick acting and cause quick onset of their hypnotic
effects. The effects generally last for six to eight hours (Caldwell ’03). However, many sleeping
pills work differently for different people. Sleeping pills often cause daytime sleepiness and
cognitive impairment. These side effects often remain until the next day, interfering with
daytime performance (Pagel and Parnes ’01). Sleeping pills can also have a diminishing effect on
brain function. This dangerous symptom is exacerbated if the antihistamine is reaching with
another drug substance that causes sedations (Caldwell ’03). They should be taken with caution
and used only as a last resort.
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A class of drugs used quite frequently in the treatment of insomnia is sedating
antidepressants. Many patients with insomnia also suffer from depressive symptoms, and
sometimes the depression is a direct result of the insomnia (Pagel and Parnes ’01). One group of
antidepressants used are the tricyclic antidepressants. Tricyclics are absorbed quickly and reach
peak blood levels in two to four hours. Tricyclics can increase deep sleep and decrease the
number of awakenings during the night (A.D.A.M. ’03). In addition, they cause a gradual
improvement in the depressed patient’s mood, although this effect only starts two to three weeks
after starting regular dosage (Tyrer ’93).
The required dose to treat insomnia is smaller than the dose used to treat depression, an
amount that often causes many negative side effects. However, even the small dose does cause a
few minor side effects such as weight gain, increased heart rate, dry mouth, and constipation. It
can also can also cause daytime sleepiness and hangover or even weakness and fainting spells
(Caldwell ’03). Tricyclics also have a high danger of overdose (Pagel and Parnes ’01).
Additionally, if a patient is taking antidepressants, especially a large dose, and abruptly
withdraws, he can suffer symptoms of severe anxiety and perhaps even panic. However,
withdrawing gradually by slowly reducing the dose over a period of four weeks can usually help
circumvent this effect (Tyrer ’93).
The main class of drugs used today in the treatment of insomnia is benzodiazepines.
Benzodiazepines act as GABA receptor agonists in the nervous system. GABA (gammaaminobutyric acid) is the chief inhibitory transmitter in the central nervous system (Pinel ’03).
There are three types of receptors for GABA in the CNS; one type is GABAᴀ receptors. The
GABAᴀ receptor controls the direction and magnitude of the ionic currents of the neuronal ion
channels. When GABA binds to the GABAᴀ receptors, it triggers the opening of a chloride ion
pore. This inhibits the firing of new action potentials. Benzodiazepines act by binding to a
different site on the GABAᴀ receptor and thereby increasing the binding of GABA molecules to
the receptor (Pinel ’03). This increases the inhibitory effects and slows down the flow of
chemical information from one neuron to another (Caldwell ’03). This is what causes the
relaxation and sedation that aid in reducing insomnia.
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Since they were developed in the 1960’s, benzodiazepines have proven their
effectiveness. Today benzodiazepines are the drugs of choice in the treatment of insomnia, since
they have the highest benefit and the lowest risk of other sleep-enhancing medications (NSF
’02). As with most sleep-promoting drugs, benzodiazepines have proven effective for decreasing
the time it takes to fall asleep, increasing total sleep time, minimizing the number of awakenings
during the night, and improving the quality of sleep (A.D.A.M. ’03). Benzodiazepines, though,
are less likely to lose efficiency after a few months (A.D.A.M. ’03), while many other drugs
require higher and higher doses to continue to work against the insomnia. In addition,
benzodiazepines have a much smaller abuse potential and overdose danger (Pagel and Parnes
’01). The therapeutic index, or the relationship between the effective dose and the lethal dose, is
about one hundred for benzodiazepines, while it is a mere two to four for drugs such as
barbiturates (Roehrs and Roth ’97). For this reason, final overdose of a benzodiazepine is
extremely rare (Caldwell ’03).
However, benzodiazepines do have certain adverse side effects. As do most hypnotics,
benzodiazepines often cause residual daytime sleepiness. Benzodiazepines inhibit the charging
of neurons in the central nervous system, and if this effect lingers, drowsiness as well as a
slowing of thought processes occurs (Caldwell ’03). Coordination and judgement are impaired
(Committee on the Review of Medicines 80’), and a general deterioration of neurological
functioning is observed (Caldwell ’03). Most often these effects are quite subtle, but occasionally
they may be severe, resulting in confusion and disorientation and memory loss of preceding
events (Caldwell ’03). This happens especially with elderly patients who are taking
benzodiazepines, as the aging brain seems to be more susceptible to this type of side effect
(Caldwell ’03). This residual drowsiness has led benzodiazepines to be associated with an
increased risk for falls and car accidents, especially within the first week of taking them
(A.D.A.M. ’03). This is why users of benzodiazepines are advised not to drive or operate heavy
machinery while on the medication.
The inhibitive properties of benzodiazepines also cause relaxation of muscles. If this effect
persists, patients will experience poor fine motor coordination and generalized weakness. A mild
spinning sensation or blurred vision may also occur (Caldwell ’03).
Benzodiazepines can also have an effect on one’s mood and may increase depression
(A.D.A.M. ’03). In addition, respiratory depression may occur as a result of taking
benzodiazepines. This happens especially in patients with preexisting respiratory disorders, for
whom the benzodiazepines exacerbate the respiratory malfunctions (Pagel and Parnes ’01).
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Some experts do not like to promote the use of benzodiazepines as they distort the normal
patterns of sleep. While benzodiazepines increase the time spent in Stage Two sleep, they
decrease the time spent in Stage Four sleep and in the restorative REM sleep (Pinel ’03). This
causes another negative side effect of benzodiazepines: the patients experiences disturbing
dreams (Caldwell ’03).
Benzodiazepines are also problematic in that tolerant to the medication and it no longer
works well as the treatment continues (Caldwell ’03). This requires the patient to take
continuously higher doses of the benzodiazepine to maintain the same results (Pinel ’01). A
study done by the White House Office of Drug Policy and the National Institute on Drug Abuse
found that many benzodiazepines tend to lose their efficacy after three to fourteen days of
continuous use (Committee on the Review of Medicines ’80).
In addition to tolerance, the body develops dependence on benzodiazepines. This is a
state in which unless drug use continues, the body will go into a withdrawal or drug-absence
stage (Caldwell ’03). If a patient taking benzodiazepines stops the medication abruptly, he will
experience many withdrawal symptoms. One symptom almost always experienced, especially by
those who have been taking benzodiazepines over a long period of time, is rebound insomnia.
This entails one to two nights of poor sleep and daytime tiredness. Patients may also suffer from
increased anxiety and apprehension and perceptual disruption of noise, touch, and movement
(Tyrer ’93). Gastrointestinal irritation and disturbed heart rhythm are common withdrawal
symptoms as well. Sometimes, patients may suffer the same severe insomnia that caused them to
start the drug in the first place (A.D.A.M. ’03). This severe rebound insomnia lasts about one to
three weeks until it returns to the level it was at before the drug was stopped (Tyrer ’93). This
can be dangerous because doctors observing the return of the original insomnia may conclude
that the treatment was ineffective and then prescribe a higher dose of the medication (Committee
on the Review of Medicines ’80).
To circumvent these withdrawal symptoms, it is advised to withdraw from the
benzodiazepine drugs gradually (Committee on the Review of Medicine ’80). This can be over a
period from two weeks to many months (Tyrer ’93). This allows enough time for the central
nervous system to adapt to the withdrawal of the inhibitory drug (Tyrer ’93).
Another suggestion to decrease the severity of withdrawal symptoms is to withdraw from
the benzodiazepines along with cognitive behavior therapy. A study done in Canada in 2003
studies the differences between gradual tapering of the benzodiazepines and gradual tapering
combined with cognitive behavior therapy. The researchers randomly assigned these two
withdrawal methods to the patients in the study who had been using benzodiazepines at bedtime
for the previous three months or longer. Out of the sixty-five patients, thirty received a gradual
tapering schedule of 25% reduction in dosage at one to two week intervals. The other thirty-five
received the same withdrawal schedule as well as a ninety-minute weekly session of therapy with
a psychologist who gave sleep hygiene education and instructions for stimulus control. Each
patient met weekly with a doctor who looked for withdrawal symptoms. Based on the patient’s
symptoms the doctor prescribed either the same or a lower dosage of the benzodiazepines. After
eight weeks of treatment an evaluation was done. The evaluation found that 38% of those
undergoing gradual tapering only had completely withdrawn from the benzodiazepines, while in
the combined group the percentage of patients off the benzodiazepines was 77%. Additionally, a
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reduction in the dosage of benzodiazepine greater than 50% occurred in 69% of the first group
and 97% of the combined patients. After a twelve month follow-up, some patients had reverted
back to taking the benzodiazepine or had increased the dosage; however, the percentages were
once again much higher for those in the combined group. This study clearly showed that the
combination of cognitive behavior therapy with gradual tapering is superior to gradual tapering
alone (Baillargeon et al. ’03).
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Due to the many adverse side effects the use of benzodiazepines entails, doctors
recommend that the regular use of benzodiazepines should be limited (Roehrs and Roth ’97).
The Committee on Safety of Medicines advised that benzodiazepines should not be used for
more than four weeks (Bashir et al. ’94). Benzodiazepines should be prescribed at the lowest
possible effective dose and prescriptions should be within the therapeutic range (Committee on
the Review of Medicines ’80)
However, there is another type of benzodiazepine that produces fewer negative side
effects. This type of benzodiazepine may be excluded from the limitation of regular
benzodiazepines due to the decreased risks it involves. These are the short-acting
benzodiazepines that have much shorter half-lives than the regular benzodiazepines. These come
very close to the “ideal sleeping pill”, as they have a quick onset, last for a typical night’s sleep
of six to eight hours, and then are quickly metabolized or eliminated from the body and the
hypotonic effects stop. (Caldwell ’03).
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There is quite a range of short half-life benzodiazepines. Some, like triazolam, have a
very rapid onset but last for only a short while. This medication can be helpful for a patient who
has difficulty falling asleep but not for a patient who tends to awaken throughout the night, as the
drug is cleared from the body before the night is over (Caldwell ’03). Other short half-life
benzodiazepines wear off by the next morning. This decreases the “hangover” side effects of
drowsiness and impaired neurological functioning (Committee on the Review of Medicines ’80).
For this reason, short-acting benzodiazepines are usually prescribed over long-acting ones for the
elderly (Hallfors and Saxe ’93).
The withdrawal symptoms from short-acting benzodiazepines differ from the symptoms
of withdrawal from long half-life benzodiazepines. In 1991 a meta-analysis was conducted of
seven studies done to determine the differences. Each of the studies had a few more dropouts of
the withdrawal from the short half-life benzodiazepines than the long half-life ones. When all the
studies were combined, the meta-analysis found the difference to be significant. Additionally, the
meta-analysis found that the patients on a short half-life benzodiazepine had a 25% greater
chance of experiencing anxiety after withdrawal than those on a long half-life benzodiazepine.
The authors concluded that patients withdrawing from short half-life benzodiazepines “may be
exceedingly uncomfortable and less likely to successfully complete withdrawal” (Hallfors and
Saxe ’93).
The claims that short half-life benzodiazepines cause excessive withdrawal symptoms
and rebound insomnia led to the banning of one such drug, triazolam, by several countries
including Britain (O’Donovan and McGuffin ’93). A review of the topic written in 1993 gave
many examples of studies that showed memory impairment and anxiety associated more with
short half-life than long half-life benzodiazepines. The United States Food and Drug
Administration received reports on adverse side effects on hundred times more commonly for
triazolam than temazepam, a different short-acting benzodiazepine with a slightly longer halflife. The review concluded that amnesia and rebound insomnia, “although not unique to
triazolam, are more often associated with its use than with other benzodiazepines.” The authors
pointed out that there are numerous treatment methods for insomnia, both pharmacological and
behavioral, and “triazolam has no compelling singular benefits that outbalance the risks”
(O’Donovan and McGuffin ’93).
However, the review warned that “obviously case reports and drug monitoring data are
open to many sources of bias, and a drug that has been the subject of media attention may attract
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closer scrutiny of its apparent adverse effects by both doctors and their patients” (O’Donovan
and McGuffin ’93). Furthermore, a letter to the editor written by two doctors in response to the
1993 review pointed out that the only countries in which triazolam is suspended are the United
Kingdom, Norway, and Brazil. The authors of the letter claimed that the evidence brought in the
review does not support the position that triazolam is more likely to produce withdrawal
symptoms than other benzodiazepines. They explained that the authors of the review gave
“enormous weight to some studies with exceptionally small sample sizes” and they showed a
“tendency to magnify some studies while minimizing large scale work.” This resulted in a
“conclusion that we believe is not supported by objective fact.” Their idea is the same conclusion
that the Collegium International Neuropsychopharmacologium and the World Psychiatric
Association reached in their reports on the subjects. They conclude that patients who use short
half-life benzodiazepines “derive remarkable benefit” (Dinan and Leonard ’93).
This conclusion is supported by other studies which claim that although the withdrawal
symptoms from a short half-life benzodiazepine occur sooner and are more severe, they last for a
shorter time than the withdrawal symptoms from long half-life benzodiazepines (Tyrer ’93). A
study was done in 1994 over a six-month period to test the effects of physician intervention
during benzodiazepine withdrawal. Incidentally, this study found that those patients on a short
half-life benzodiazepine were more likely to reduce their dosage than those on a long half-life
benzodiazepine. The authors pointed out that the current trend was to switch short half-life
benzodiazepine users to a long half-life benzodiazepine when considering withdrawal, as the
shorter half-life benzodiazepines were thought to have increased risks of withdrawal symptoms.
However, the authors suggested based on their results that “it may be better to leave patients on
their short-acting preparations when a dose reduction is being attempted” (Bashir et al. ’94).
Some Long- and Short-Acting Benzodiazepines and Their Commercial Names
Long-Acting
Short-Acting
chlorazepate (Genene, Tranxene)
alprazolam (Apro-Alprax, Xanax)
chlordiazepoxide (Librax, Librium)
bromazepam (Lectopam)
clonazepam (Klonopin, Rivotril)
estazolam (ProSom)
diazepam (Valium, Rivotril)
fluntitrazepam (Rohypnol)
flurazepam (Dalmane, Somnol)
halazepam (Paxipan)
nitrazepam (Inomax, Mogadon)
ketazolam (Loftan)
quazepam (Doral)
lorazepam (Ativan, Nu-Luraz)
midazolam (Versed)
oxazepam (Serax)
prazepam (Centrax)
temazepam (Restoril)
triazolam (Halcion, Nutriazo)
Although benzodiazepines are currently most often prescribed hypnotic, a new group of
drugs called benzodiazepines receptor agonists (BZRAs), is increasingly being prescribed and is
becoming the new hypnotic drug of choice (A.D.A.M. ’03). These non- benzodiazepine BZRAs
are even shorter acting than short half-life benzodiazepines and include “Z drugs” zolpidem,
zaleplon, and zopiclone, known commercially as Ambien, Sonata, and Imovane.
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The National Institute for Clinical Excellence (NICE) in Britain recommends that
hypnotic drugs be used only for short periods. In their guidance, they do not distinguish between
short-acting benzodiazepines and the BZRAs, explaining that they have found “no compelling
evidence of a clinically useful difference” between them. Instead, they recommend using the
drug with the “lowest purchase cost” (Gibson ’04). However, many researchers and practitioners
disagree with NICE’s conclusion. The British Sleep Society, a professional organization of
medical and scientific staff who focus on sleep disorders, does not support NICE’s decision.
Professor David Nutt, the society’s representative, expressed that “it seems perverse that patients
will be forced to run the risk of significant daytime hangover to save a few pence on drug costs”
(Gibson ’04).
Just like the British Sleep Society, many physicians believe that BZRAs have fewer side
effects than even short half-life benzodiazepines (Pagel and Parnes ’01). Although they might
produce minimal early-morning confusion and nausea (Caldwell ’03), BZRAs have much lower
risk of lingering sedative effects that will interfere with daytime functioning (Zammitt and
Kramer ’01). This is especially helpful in the treatment of elderly patients, when this results in
fewer risks for falls or memory loss (A.D.A.M. ’03). BZRAs only slightly alter sleep patterns,
and their potential for abuse is minimal (Pagel and Parnes ’01). In patients with respiratory
disorders, BZRAs have fewer respiratory suppressant effects (Pagel and Parnes ’01). They have
a lower risk than benzodiazepines for tolerance and dependence (Lieberman ’07). Studies done
to evaluate the long-term effectiveness and safety of BZRAs showed that discontinuation did not
produce withdrawal symptoms (Zammitt and Kramer ’01). The drawback to BZRAs, however, is
that these drugs are expensive (A.D.A.M/ ’03).
Most recently, Evotec, a research company that “is a leader in the discovery and
development of novel small molecule drugs” (WebWire ’06), has been working on a new drug to
treat insomnia. This drug, labelled EVT 201, is a partial agonist of the GABAᴀ receptor. As a
partial agonist, it employs a difference mechanism than benzodiazepines and BZRAs which are
full agonists of the GABAᴀ receptor.
EVT 201 is currently in the middle of extensive testing process conducted on all new
drugs. It recently completed a Phase II clinical trial conducted on sixty-seven patients in sleep
labs in the United States. This trial showed that the drug caused significant improvements in the
quality of sleep, measured both by subjective assessments and polysomnography. The subjects in
the trial did not report any residual sedation. In this trial, EVT 201 was shown to be safe and
well-accepted without any significant adverse effects (WebWire ’06).
In further trials to be conducted on the drug, additional measures will be studies and
researchers will check for any adverse effects. Dr. John Kemp, Chief Research and Development
Officer in the Evotec company, pronounced, “If we can confirm this profile of efficacy together
with freedom from significant adverse effects in patients with primary insomnia, this would
represent a very attractive product in a market in which we believe there are significant
opportunities based on a high unmet medical need” (WebWire ’06). Perhaps in a few years from
now, EVT 201 will be the only medication that can be found on the shelf in the insomnia section
of the pharmacy.
The way people think about insomnia has changed drastically over the past fifty years. In
the past, if someone complained of having sleep difficulties, “medications that were often
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dangerous and addictive were prescribed to induce sleep, while the basis of the patient’s
complaint was not addressed” (Pagel and Parnes ’01). Today, however, the safety of treatments
has improved (Lieberman ’07), and researchers are still working on finding drugs with better
results and fewer adverse side effects. Additionally, our understanding of sleep has grown
tremendously, and we are better able to pinpoint the source of the insomnia and treat
accordingly. Doctors now understand that not all cases of insomnia are alike. From the
psychological, biological, or physiological factors that caused the insomnia, to the
endocrinological, behavioral, and emotional outcomes that result, no two cases of insomnia are
perfectly alike. Consequently, each case must be treated differently. A method that produced
wonderful results when used for Patient X might backfire when tried for Patient Y. Each case of
insomnia is unique, and the plethora of treatments available today allows the practitioner to find
and prescribe the ones that will work best for each patient.
CONCLUSION
Insomnia is a condition that can happen to anyone. Whether due to improper sleep
hygiene, consumption of beverages such as caffeine or nicotine, as a side effect from a particular
medication, or during a period of depression, many people are susceptible and may become
unable to sleep. This can be dangerous, because as this paper has shown the resulting sleep
deprivation has many significant negative consequences. Not only do these effects persist as long
as the insomnia lasts, we have seen that some results may have lifelong repercussions.
Fortunately, though, there are many treatments available to help in the battle against insomnia.
This paper has discussed a few behavioral techniques that are helpful. Additionally, this paper
has presented many medications that are used to treat insomnia and has explained the benefits
and risks of each type. This paper has shown that although drugs might be more effective than
behavioral techniques for many people, no medication is perfectly effective or completely free
from negative side effects. Thus, any patient suffering from insomnia must discuss with his
doctor the various remedies, weighing the risks and benefits of each. They will then be able to
choose the treatment or treatments that will help with his individual case and will best cure him
of his insomnia.
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